Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment

Leqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.

from Business News https://ift.tt/RAJbpgf